Please upgrade your browser.
Pfizer of New York City released disappointing results of a trial in advanced renal cell carcinoma
In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population.
Tumour-treating electrical fields, a Victorian gout remedy, and an anti-cancer 'virusâ. Meet the scientists tackling our most feared disease in some truly innovative ways
The Consumer Reports magazine issue of September 2012 notes on page 22 that "far from reducing cancer risk, as a lot of people believe, high doses of some antioxidant supplements may actually increase it, evidence suggests."
In an effort to increase efficacy, we studied the effects of increased sorafenib dose and intermittent scheduling in a murine RCC xenograft model.
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy
Hyponatremia is reported to be associated with poor survival in localized renal cell carcinoma and metastatic renal cell carcinoma treated with immunotherapy.
Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy.
However, survival is now roughly double what was seen before targeted therapy.
Recent studies using a variety of pharmacological inhibitors and genetic models of HDACs have revealed a central role of HDACs in control of kidney development.
C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied.
|Powered by NeonCRM|